Tech Company Financing Transactions

Aeglea BioTherapeutics Funding Round

Aeglea BioTherapeutics, operating out of Austin, scored $44 million in funding from Lilly Ventures, Novartis Venture Fund and Ally Bridge Group.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

901 S. MoPac Expy. Barton Oaks Plz. One 250
Austin, TX 78746
USA

Phone

(512) 942-2935

Website

www.aegleabio.com

Email Address

[email protected]

Overview

Aeglea BioTherapeutics (NASDAQ: AGLE) is developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Anthony Quinn

        

Chief Financial Officer

Charles York

        

Chief Medical Officer

James Wooldridge

        

Chief Operating Officer

Leslie Sloan

        

VP - R & D

Scott Rowlinson

        

Browse more venture capital transactions:

Prev: 3/23/2015: Canon U.S.A. venture capital transaction
Next: 3/24/2015: 1366 Technologies venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary